Skip to main content
Wolverine Prescribed

A distilled field-record of the BPC-157 + TB-500 research blend — the two-peptide pairing pressed down to what the literature actually establishes, with its regulatory and compounded-access status set first.

The papers and federal pages behind the facts

BPC-157 TB-500 References You Can Bring to a Visit

Each note on this site points to a medical paper or a federal pharmacy page. You can use the list to ask which source supports a claim.

Return to the studiesCheck the pharmacy rules

What these sources let you check for yourself

A clinic claim is easier to judge when you can see its source. These BPC-157 TB-500 references show where each number began.

The list runs from early animal work [1] through newer reviews [11]. It includes a study of how BPC-157 left animal blood [5] and two Phase 1 tests, the first small safety tests, of Thymosin Beta-4 [6][7].

Federal pages let you check the past safety warning [12] and the later committee review [14]. The full entries below keep the lab names and paper numbers for anyone who wants them.

If you take a paper to your visit, I'd ask how its animals or volunteers compare with you. A careful doctor won't turn a rat result into a promise for your knee.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  6. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. ↗
  7. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(16):7755-7765. ↗
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (FDA placed BPC-157 and the thymosin beta-4 fragment known as TB-500 in Category 2 on September 29, 2023; its page, current as of April 22, 2026, says the nominations were withdrawn and no longer lists either substance in that category.) ↗
  13. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Category definitions; the 503A/503B framework; the January 7, 2025 change to categorization of newly nominated substances; verified 2026-05-29.) ↗
  14. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500, with KPV and MOTS-c, as bulk drug substances 'being considered for inclusion on the 503A Bulks List' — a scheduled discussion, not a decision; verified 2026-05-29.) ↗
  15. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  16. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗